Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.
Othman, Ahmed A
Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. [electronic resource] - Clinical pharmacology in drug development 05 2019 - 492-502 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2160-7648
10.1002/cpdd.611 doi
Adult
Aged
Antibodies, Monoclonal--administration & dosage
Area Under Curve
Arthritis, Rheumatoid--drug therapy
Double-Blind Method
Drug Administration Schedule
Female
Healthy Volunteers
Humans
Injections, Subcutaneous
Interleukin-17--antagonists & inhibitors
Male
Middle Aged
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Young Adult
Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. [electronic resource] - Clinical pharmacology in drug development 05 2019 - 492-502 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2160-7648
10.1002/cpdd.611 doi
Adult
Aged
Antibodies, Monoclonal--administration & dosage
Area Under Curve
Arthritis, Rheumatoid--drug therapy
Double-Blind Method
Drug Administration Schedule
Female
Healthy Volunteers
Humans
Injections, Subcutaneous
Interleukin-17--antagonists & inhibitors
Male
Middle Aged
Tumor Necrosis Factor-alpha--antagonists & inhibitors
Young Adult